Fortress Biotech, Inc. Amendment to Schedule 13D for Mustang Bio, Inc.

Fortress Biotech, Inc. has filed an amendment to its Schedule 13D regarding its holdings in Mustang Bio, Inc. The amendment reflects changes in the ownership structure, including the issuance of 59,334 shares of Mustang Bio's common stock as Offering Equity Grants under the Founders Agreement. Fortress Biotech holds 258,858 shares of Mustang Bio's common stock, representing a 4.0% ownership stake. This includes 250,000 shares of Class A preferred stock, which are convertible into 333 shares of common stock. The amendment also details the terms of the Founders Agreement, which entitles Fortress Biotech to an equity fee in the form of Mustang Bio common stock equal to 2.5% of the gross amount of any equity or debt financing. The filing includes exhibits such as the Amended and Restated Certificate of Incorporation and the Second Amended and Restated Founders Agreement.